The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

In a head-to-head clinical trial funded by Eli Lilly, Zepbound, which is tirzepatide, outperformed Novo Nordisk’s Wegovy, a semaglutide, across all major measures of weight loss over 72 weeks.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...